Inspyr Therapeutics Reports Financial Results and Business Update For Full Year 2020

Rhea-AI Summary

Inspyr Therapeutics has implemented a new corporate strategy focused on precision therapeutics for cancer treatment, acquiring a proprietary portfolio of adenosine immuno-modulator compounds. The lead asset, RT-AR001, is on track for pre-IND filing in H1 2021. The firm has strengthened its pipeline and increased its cash runway to mid-2022, securing $1.25 million from an existing investor. Financially, Inspyr reported a net loss of $6.36 million for 2020, with cash and restricted cash rising to $404,000 from $23,000 in 2019.

Positive

• Acquired a proprietary portfolio of adenosine immuno-modulator compounds.
• Lead asset RT-AR001 on track for pre-IND filing in H1 2021.
• Increased cash runway to mid-2022 with $1.25 million secured.

Negative

• Net loss increased to $6.36 million in 2020 from $988,000 in 2019.
• Operating expenses rose to $2.48 million in 2020, largely due to licensing costs.

• Implements new corporate strategy to focus on precision therapeutics for the treatment of cancer
• Strengthens pipeline by acquiring a proprietary portfolio of novel adenosine immuno-modulator compounds
• Lead asset, RT-AR001, pre-IND filing is on track for the first half of 2021
• Increased cash runway through mid-year 2022 by securing an aggregate of $1,250,000 of gross proceeds from an existing institutional investor in 2020 and 2021.

WESTLAKE VILLAGE, CA / ACCESSWIRE / April 1, 2021 / Inspyr Therapeutics, Inc. (OTC:NXPX), a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer, today reported its financial results and business update for the fourth quarter and full year 2020 ended December 31, 2020.

Business Highlights

• In October 2020, we announced that the company would strengthen its strategic collaboration with Ridgeway Therapeutics by reacquiring its novel immune-oncology precision targeting platform for the treatment of cancer through the cancellation of our prior licensing agreement.
• As of March 30, 2021, we have 24 issued patents in our intellectual property portfolio for 22 jurisdictions in potential future commercial markets including the United States, Europe, the United Kingdom, Asia, and other geographies.
• The company is currently preparing an investigational new drug (IND) application, for its lead asset, RT-AR001, an adenosine A_2B receptor antagonist. The company plans to provide an update on RT-AR001's clinical development in the second half of 2021 after its pre-IND meeting with the U.S. Food and Drug Administration (FDA).

Financial Highlights

• Cash and restricted cash was $0.4 million and $0.02 million at December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019, there was no cash over the federally insured limit.
• Operating expenses was $2.5 million and $0.06 million at December 31, 2020 and 2019, respectively. The increase was mostly due to the $2.0 million associated with the licensing cost of the adenosine portfolio.
• Research and development (R&D) expenses incurred were $0.02 million and $0.04 million for the years ended December 31, 2020 and 2019, respectively.

Financial Results for the Fourth Quarter and Full Year Ended December 31, 2020

INSPYR THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)

		December 31,
		2020				2019
ASSETS
Current assets:
Cash		$	404			$	4
Restricted cash			-				19
Total current assets			404				23
Total assets		$	404			$	23
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable		$	2,261			$	2,269
Accrued expenses			1,940				1,866
Convertible debentures, net of unamortized discount of $488 and $281			1,878				2,826
Derivative liability			6,828				1,785
Total current liabilities			12,907				8,746
Total liabilities			12,907				8,746
Commitments and contingencies (Note 8)			-				-
Stockholders' deficit:
Convertible preferred stock, undesignated, par value $.0001 per share; 29,978,846 shares authorized, no shares issued and outstanding, respectively			-				-
Convertible preferred stock Series A, par value $.0001 per share; 1,854 shares authorized, 134 shares issued and outstanding, respectively			-				-
Convertible preferred stock Series B, par value $.0001 per share; 1,000 shares authorized, 71 shares issued and outstanding, respectively			-				-
Convertible preferred stock Series C, par value $.0001 per share; 300 shares authorized, 290 shares issued and outstanding, respectively			-				-
Convertible preferred stock Series D, par value $.0001 per share; 5,000 shares authorized, 5,000 and 5,000 shares issued and outstanding, respectively			-				-
Convertible preferred stock Series E, par value $.0001 per share; 5,000 shares authorized, 5,000 and no shares issued and outstanding, respectively			-				-
Convertible preferred stock Series F, par value $.0001 per share; 8,000 shares authorized, 8,000 and no shares issued and outstanding, respectively			-				-
Common stock, par value $.0001 per share; 1,000,000,000 shares authorized, 185,625,000 and 623,382 shares issued and outstanding, respectively			19				-
Additional paid-in capital			54,453				51,957
Accumulated deficit			(66,975	)			(60,680	)
Total stockholders' deficit			(12,503	)			(8,723	)
Total liabilities and stockholders' deficit		$	404			$	23

INSPYR THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF LOSSES
(in thousands, except share and per share data)

		Years Ended December 31,
		2020				2019
Operating expenses:
Research and development		$	18			$	44
License termination cost			1,969				-
General and administrative			494				565
Total operating expenses			2,481				609
Loss from operations			(2,481	)			(609	)
Other income (expense):
Gain (loss) on change in fair value of derivative liability			(3,846	)			327
Gain on conversion of debt			334				125
Interest (expense), net			(302	)			(777	)
Loss before provision for income taxes			(6,295	)			(934	)
Provision for income taxes			-				-
Net loss			(6,295	)			(934	)
Deemed dividend			(64	)			(54	)
Net loss attributable to common shareholders		$	(6,359	)		$	(988	)
Net loss per common share, basic and diluted		$	(0.14	)		$	(4.22	)
Weighted average shares outstanding			43,343,388				234,345

INSPYR THERAPEUTICS, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT
FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019
(in thousands, except share and per share data)

		ConvertiblePreferred Stock								Common Stock								AdditionalPaid-in				Accumulated				Stockholders'
		Shares				Amount				Shares				Amount				Capital				Deficit				Deficit
Balance, December 31, 2018			495			$	-				114,508			$	-			$	51,479			$	(59,746	)		$	(8,267	)
Sale of preferred stock			5,000				-				-				-				5				-				5
Conversion of notes			-				-				508,874				-				473				-				473
Net loss			-				-				-				-				-				(934	)			(934	)
Balance, December 31, 2019			5,495				-				623,382				-				51,957				(60,680	)			(8,723	)
Sale of preferred stock			5,000				-				-				-				5				-				5
Issuance of preferred stock for license termination			8,000				-				-				-				-				-				-
Issuance of common stock for license termination			-				-				65,000,000				7				260				-				267
Conversion of notes			-				-				120,001,618				12				2,231				-				2,243
Net loss			-				-				-				-				-				(6,295	)			(6,295	)
Balance, December 31, 2020			18,495			$	-				185,625,000			$	19			$	54,453			$	(66,975	)		$	(12,503	)

INSPYR THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

		Years Ended December 31,
		2020				2019
Cash flows from operating activities:
Net loss		$	(6,295	)		$	(934	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			-				36
Common and preferred stock issued for license termination			1,944				-
(Gain) loss on change in fair value of derivative liability			3,846				(327	)
Gain on conversion of debt			(334	)			(125	)
Amortization of debt discount			280				281
Finance cost			20				494
Increase in operating liabilities:
Accounts payable and accrued expenses			165				262
Cash used in operating activities			(374	)			(313	)
Cash flows from investing activities:
Cash provided by investing activities			-				-
Cash flows from financing activities:
Proceeds from convertible notes			750				-
Proceeds from sale of preferred stock			5				5
Cash provided by financing activities			755				5
Net increase (decrease) in cash and restricted cash			381				(308	)
Cash and restricted cash, beginning of year			23				331
Cash and restricted cash, end of year		$	404			$	23

About Inspyr Therapeutics, Inc.

Inspyr Therapeutics, Inc is a pharmaceutical company focused on the research and development of novel targeted precision therapeutics for the treatment of cancer. Our approach utilizes our proprietary delivery technology to better enhance immuno-modulation for improved therapeutic outcomes. Our potential first-in-class immune-oncology lead asset, RT-AR001, an adenosine A2 receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allows for better tumor infiltration. The adenosine A2 Receptor is one of many T-cell surface immune checkpoint proteins.. Our patented portfolio of adenosine receptor antagonists provides flexibility to optimize treatment based on the specific adenosine targets found in each type of cancer.

Cautionary Statement Regarding Forward Looking Information:

This news release contains "forward-looking statements" made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and may often be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "seek" or "will." Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Specific risks and uncertainties that could cause our actual results to differ materially from those expressed in our forward-looking statements include risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Inspyr Therapeutic's periodic reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Reports on Form 10-Q as well as and in other reports filed with the SEC. We do not assume any obligation to update any forward-looking statements.

Contact: investors@inspyrx.com

SOURCE: Inspyr Therapeutics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/638666/Inspyr-Therapeutics-Reports-Financial-Results-and-Business-Update-For-Full-Year-2020

FAQ

What are the financial results for Inspyr Therapeutics for 2020?

Inspyr Therapeutics reported a net loss of $6.36 million for the year ended December 31, 2020.

What is the status of RT-AR001?

RT-AR001 is on track for pre-IND filing in the first half of 2021.

How much cash does Inspyr Therapeutics have?

As of December 31, 2020, Inspyr had cash and restricted cash of $404,000.

What was the impact of operating expenses on Inspyr's finances?

Operating expenses increased to $2.48 million in 2020, mostly due to licensing costs related to the adenosine portfolio.

How has Inspyr's cash runway changed?

Inspyr secured $1.25 million from an existing investor, extending its cash runway through mid-2022.